Saudi Central Bank Increases Stake in Becton, Dickinson and Company $BDX

Saudi Central Bank lifted its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 89.6% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 19,951 shares of the medical instruments supplier’s stock after buying an additional 9,431 shares during the period. Saudi Central Bank’s holdings in Becton, Dickinson and Company were worth $3,019,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Imprint Wealth LLC purchased a new stake in shares of Becton, Dickinson and Company in the third quarter valued at $25,000. SHP Wealth Management acquired a new position in Becton, Dickinson and Company in the fourth quarter valued at $26,000. Meeder Asset Management Inc. increased its position in Becton, Dickinson and Company by 152.2% during the 1st quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 102 shares in the last quarter. Main Street Group LTD purchased a new position in shares of Becton, Dickinson and Company in the 1st quarter valued at $29,000. Finally, Bell Investment Advisors Inc purchased a new position in Becton, Dickinson and Company in the second quarter valued at about $29,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the company. Piper Sandler raised their target price on Becton, Dickinson and Company from $161.00 to $175.00 and gave the company a “neutral” rating in a research note on Friday, August 7th. Barclays upped their target price on Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an “overweight” rating in a report on Monday, May 11th. Evercore set a $180.00 target price on shares of Becton, Dickinson and Company in a research report on Monday, July 6th. Wells Fargo & Company boosted their price target on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an “equal weight” rating in a research report on Friday, August 7th. Finally, The Goldman Sachs Group lowered their target price on Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating on the stock in a report on Wednesday, May 27th. Eight investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $187.67.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael Feld sold 165 shares of the company’s stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total transaction of $31,100.85. Following the transaction, the executive vice president directly owned 19,720 shares in the company, valued at approximately $3,717,022.80. This represents a 0.83% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas Polen, Jr. sold 4,152 shares of the firm’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $185.00, for a total transaction of $768,120.00. Following the completion of the transaction, the chief executive officer directly owned 110,163 shares in the company, valued at approximately $20,380,155. The trade was a 3.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 9,105 shares of company stock valued at $1,590,208. 0.40% of the stock is owned by company insiders.

Becton, Dickinson and Company Stock Up 0.0%

BDX stock opened at $184.78 on Tuesday. Becton, Dickinson and Company has a 52-week low of $127.59 and a 52-week high of $193.07. The stock has a market capitalization of $50.91 billion, a price-to-earnings ratio of 55.66, a price-to-earnings-growth ratio of 13.02 and a beta of 0.21. The company has a 50-day moving average of $170.65 and a two-hundred day moving average of $160.63. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, beating the consensus estimate of $3.14 by $0.09. The business had revenue of $4.98 billion during the quarter, compared to analysts’ expectations of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The firm’s revenue was up 5.4% on a year-over-year basis. During the same quarter last year, the company earned $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, equities research analysts anticipate that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be given a dividend of $1.05 per share. The ex-dividend date is Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.3%. Becton, Dickinson and Company’s payout ratio is presently 126.51%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.